Paloma Partners Management Co Buys 31,226 Shares of Eli Lilly And Co (NYSE:LLY)

Paloma Partners Management Co boosted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 723.7% during the second quarter, Holdings Channel.com reports. The firm owned 35,541 shares of the company’s stock after purchasing an additional 31,226 shares during the quarter. Paloma Partners Management Co’s holdings in Eli Lilly And Co were worth $3,938,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in LLY. Meridian Wealth Management LLC acquired a new position in Eli Lilly And Co during the 1st quarter worth $38,000. Manchester Financial Inc. purchased a new stake in Eli Lilly And Co in the second quarter valued at approximately $40,000. Litman Gregory Asset Management LLC purchased a new stake in Eli Lilly And Co in the second quarter valued at approximately $47,000. Personal Wealth Partners purchased a new stake in Eli Lilly And Co in the second quarter valued at approximately $53,000. Finally, Kavar Capital Partners LLC purchased a new stake in Eli Lilly And Co in the second quarter valued at approximately $55,000. Institutional investors own 76.72% of the company’s stock.

A number of equities research analysts recently weighed in on the stock. Goldman Sachs Group assumed coverage on shares of Eli Lilly And Co in a research note on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Bank of America set a $120.00 target price on shares of Eli Lilly And Co and gave the company a “neutral” rating in a research note on Tuesday, September 10th. Finally, ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Friday, June 28th. Nine investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and a consensus target price of $122.93.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 19,500 shares of Eli Lilly And Co stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the transaction, the senior vice president now directly owns 38,306 shares of the company’s stock, valued at $4,325,130.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Stephen F. Fry sold 9,452 shares of Eli Lilly And Co stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $115.00, for a total transaction of $1,086,980.00. Following the transaction, the senior vice president now directly owns 100,211 shares in the company, valued at $11,524,265. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.

LLY traded up $1.94 on Friday, reaching $116.29. The company had a trading volume of 175,677 shares, compared to its average volume of 3,039,316. The company has a market cap of $112.87 billion, a price-to-earnings ratio of 20.96, a P/E/G ratio of 1.92 and a beta of 0.16. Eli Lilly And Co has a 52-week low of $104.17 and a 52-week high of $132.13. The business has a 50 day simple moving average of $111.96 and a 200 day simple moving average of $116.46. The company has a debt-to-equity ratio of 4.98, a quick ratio of 0.87 and a current ratio of 1.13.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.45 by $0.05. The firm had revenue of $5.64 billion for the quarter, compared to the consensus estimate of $5.59 billion. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The business’s revenue was up .9% compared to the same quarter last year. During the same period last year, the firm posted $1.48 earnings per share. As a group, equities research analysts predict that Eli Lilly And Co will post 5.73 EPS for the current fiscal year.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Stock Split

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.